Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, yet development halted after Phase 1 due to kidney safety signals.

Overview

Adipotide (also known as FTPP or prohibitin-targeting peptide 1) is a synthetic peptidomimetic composed of two functional domains: a targeting sequence that binds to prohibitin on the surface of blood vessels supplying white adipose tissue, and a pro-apoptotic peptide sequence (D(KLAKLAK)2) that disrupts mitochondrial membranes upon internalization. This dual-action design was developed at the University of Texas MD Anderson Cancer Center and represents a vascular-targeting approach to fat reduction, analogous to anti-angiogenic strategies used in oncology.

In preclinical studies using obese rhesus monkeys, adipotide treatment resulted in significant reductions in body weight and body mass index over a four-week period, accompanied by decreased waist circumference and improved insulin resistance. The mechanism involves selective ablation of the blood vessels feeding white adipose tissue, leading to apoptosis of adipocytes deprived of their vascular supply. Magnetic resonance imaging confirmed preferential loss of visceral and subcutaneous fat depots. However, the treated animals also exhibited reversible renal changes, including proximal tubule injury, likely due to peptide accumulation in the kidneys.

Adipotide has not progressed to approved clinical use and remains an experimental compound. The renal toxicity observed in primate studies represents a significant safety concern that would need to be addressed through dose optimization or structural modification. Despite these challenges, the compound has contributed to the broader understanding of vascular-targeted therapies for metabolic disease and has stimulated research into prohibitin-binding peptides as potential drug delivery vehicles for adipose tissue-directed interventions.

Mechanism of Action

Vascular Targeting Mechanism

Adipotide (CKGGRAKDC-GG-D(KLAKLAK)2) is a chimeric peptidomimetic consisting of two functional domains: a targeting peptide (CKGGRAKDC) that homes to white adipose tissue vasculature, and a pro-apoptotic peptide (D(KLAKLAK)2) that disrupts mitochondrial membranes (PMID: 21890822).

Prohibitin Receptor Binding

The CKGGRAKDC motif binds specifically to prohibitin, a multifunctional protein expressed on the luminal surface of endothelial cells in white adipose tissue vasculature. Prohibitin acts as a vascular homing receptor, concentrating Adipotide selectively in adipose tissue blood vessels and enabling receptor-mediated endocytosis.

Mitochondrial Membrane Disruption

Upon internalization, the D-amino acid pro-apoptotic domain D(KLAKLAK)2 (resistant to proteolysis) targets the inner mitochondrial membrane. The amphipathic peptide inserts into the lipid bilayer, disrupting membrane potential (ΔΨm), collapsing the proton gradient, and triggering cytochrome c release into the cytosol.

Apoptotic Cascade in Endothelial Cells

Released cytochrome c activates the apoptosome (Apaf-1/caspase-9 complex), initiating the intrinsic apoptotic cascade through effector caspases 3 and 7. Endothelial cell apoptosis causes vascular regression in adipose tissue, depriving adipocytes of oxygen and nutrient supply.

Adipose Tissue Remodeling

Vascular regression leads to adipocyte atrophy and death through ischemia. In rhesus monkey studies, Adipotide treatment produced 11% body weight loss over 28 days with corresponding reductions in abdominal circumference, BMI, and improved insulin sensitivity (PMID: 21890822). Renal toxicity (reversible proximal tubule changes) has been noted as a dose-limiting effect.

Reconstitution Calculator

Safety Profile

Safety Profile: Adipotide (FTPP - Prohibitin-Targeting Peptide)

Common Side Effects

• Renal effects: Transient elevation in serum creatinine and BUN observed consistently in primate studies
• Dehydration and increased thirst due to renal concentrating defect
• Injection site reactions (pain, erythema, induration)
• Fatigue and lethargy, particularly during initial treatment
• Mild proteinuria (protein in urine)
• Nausea and decreased appetite (may be partly therapeutic mechanism-related)

Serious Adverse Effects

• Nephrotoxicity (PRIMARY CONCERN): Adipotide targets prohibitin on vascular endothelium supplying adipose tissue, but prohibitin is also expressed in renal proximal tubule cells. Dose-dependent acute kidney injury was observed in rhesus monkey studies, with creatinine elevations 2-3x baseline
• Renal tubular damage: Proximal tubular necrosis documented in preclinical studies; may be partially reversible upon cessation
• Dehydration and electrolyte imbalances (hyponatremia, hypokalemia) secondary to renal effects
• Potential off-target vascular damage in non-adipose tissues
• Immune complex formation against the targeting peptide with repeated dosing
• No human clinical trial data available; all safety information from primate and rodent studies

Contraindications

• Pre-existing renal disease or impaired kidney function (eGFR <60 mL/min)
• Dehydration or conditions predisposing to dehydration
• Concurrent nephrotoxic medication use (NSAIDs, aminoglycosides, contrast agents)
• Pregnancy and lactation
• Known hypersensitivity to peptide therapeutics
• Cardiovascular disease with compromised renal perfusion
• Not approved for human use by any regulatory authority; research compound only

Drug Interactions

• Nephrotoxic agents (NSAIDs, aminoglycosides, vancomycin, cisplatin, contrast dyes): Synergistic renal toxicity; concomitant use strongly contraindicated
• ACE inhibitors/ARBs: May potentiate renal effects; if co-administered, requires intensive renal monitoring
• Diuretics: Compounded dehydration and electrolyte depletion risk
• Metformin: Increased risk of lactic acidosis if renal function declines
• Lithium: Renal impairment may decrease lithium clearance leading to toxicity
• Antihypertensives: Adipotide-related dehydration may cause orthostatic hypotension

Population-Specific Considerations

• Pregnancy (Absolutely Contraindicated): Prohibitin targeting may disrupt placental vasculature. Severe risk of fetal harm through vascular disruption and impaired nutrient delivery. No reproductive studies; assumed teratogenic
• Pediatric: Contraindicated. Developing vasculature and renal system at high risk. No indication for pediatric obesity with this agent
• Elderly: Extreme caution. Age-related decline in renal function dramatically increases nephrotoxicity risk. Baseline GFR must be assessed. Not recommended in patients >65 due to limited reserve capacity for renal injury recovery

Pharmacokinetic Profile